1.WH. O: Global tuberculosis report 2018. . 2018.
2.Prasad R: Multidrug and extensively drug-resistant TB (M/XDR-TB): problems and solutions. The Indian journal of tuberculosis 2010, 57(4):180–191.
3.Gillespie SH: Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrobial agents and chemotherapy 2002, 46(2):267–274.
4.Schon T, Jureen P, Chryssanthou E, Giske CG, Kahlmeter G, Hoffner S, Angeby K: Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact? The Journal of antimicrobial chemotherapy 2013, 68(9):2074–2077.
5.Mariam DH, Mengistu Y, Hoffner SE, Andersson DI: Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2004, 48(4):1289–1294.
6.Ohno H, Koga H, Kohno S, Tashiro T, Hara K: Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Antimicrob Agents Chemother 1996, 40(4):1053–1056.
7.Somoskovi A, Parsons LM, Salfinger M: The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respiratory research 2001, 2(3):164–168.
8.Rigouts L, Gumusboga M, de Rijk WB, Nduwamahoro E, Uwizeye C, de Jong B, Van Deun A: Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J Clin Microbiol 2013, 51(8):2641–2645.
9.Van Deun A, Barrera L, Bastian I, Fattorini L, Hoffmann H, Kam KM, Rigouts L, Rusch-Gerdes S, Wright A: Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. Journal of clinical microbiology 2009, 47(11):3501–3506.
10.Van Deun A, Aung KJ, Bola V, Lebeke R, Hossain MA, de Rijk WB, Rigouts L, Gumusboga A, Torrea G, de Jong BC: Rifampin drug resistance tests for tuberculosis: challenging the gold standard. Journal of clinical microbiology 2013, 51(8):2633–2640.
11.Marsili L, Pasqualucci CR, Vigevani A, Gioia B, Schioppacassi G, Oronzo G: New rifamycins modified at positions 3 and 4. Synthesis, structure and biological evaluation. The Journal of antibiotics 1981, 34(8):1033–1038.
12.Uzun M, Erturan Z, Ang O: Investigation of cross-resistance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease 2002, 6(2):164–165.
13.Berrada ZL, Lin SY, Rodwell TC, Nguyen D, Schecter GF, Pham L, Janda JM, Elmaraachli W, Catanzaro A, Desmond E: Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex. Diagn Microbiol Infect Dis 2016, 85(2):177–181.
14.Jamieson FB, Guthrie JL, Neemuchwala A, Lastovetska O, Melano RG, Mehaffy C: Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis. J Clin Microbiol 2014, 52(6):2157–2162.
15.Abbadi SH, Sameaa GA, Morlock G, Cooksey RC: Molecular identification of mutations associated with anti-tuberculosis drug resistance among strains of Mycobacterium tuberculosis. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 2009, 13(6):673–678.
16.Hillemann D, Weizenegger M, Kubica T, Richter E, Niemann S: Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. Journal of clinical microbiology 2005, 43(8):3699–3703.
17.Minh NN, Van Bac N, Son NT, Lien VT, Ha CH, Cuong NH, Mai CT, Le TH: Molecular characteristics of rifampin- and isoniazid-resistant mycobacterium tuberculosis strains isolated in Vietnam. Journal of clinical microbiology 2012, 50(3):598–601.
18.Zaw MT, Emran NA, Lin Z: Mutations inside rifampicin-resistance determining region of rpoB gene associated with rifampicin-resistance in Mycobacterium tuberculosis. J Infect Public Health 2018, 11(5):605–610.
19.Chen L, Gan X, Li N, Wang J, Li K, Zhang H: rpoB gene mutation profile in rifampicin-resistant Mycobacterium tuberculosis clinical isolates from Guizhou, one of the highest incidence rate regions in China. The Journal of antimicrobial chemotherapy 2010, 65(6):1299–1301.
20.Lu J, Jiang S, Ye S, Deng Y, Ma S, Li CP: Sequence analysis of the drugresistant rpoB gene in the Mycobacterium tuberculosis Lform among patients with pneumoconiosis complicated by tuberculosis. Mol Med Rep 2014, 9(4):1325–1330.
21.Islam MM, Hameed HMA, Mugweru J, Chhotaray C, Wang C, Tan Y, Liu J, Li X, Tan S, Ojima I et al: Drug resistance mechanisms and novel drug targets for tuberculosis therapy. J Genet Genomics 2017, 44(1):21–37.
22.Torres MJ, Criado A, Gonzalez N, Palomares JC, Aznar J: Rifampin and isoniazid resistance associated mutations in Mycobacterium tuberculosis clinical isolates in Seville, Spain. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease 2002, 6(2):160–163.
23.Chen J, Peng P, Du Y, Ren Y, Chen L, Rao Y, Wang W: Early detection of multidrug- and pre-extensively drug-resistant tuberculosis from smear-positive sputum by direct sequencing. BMC infectious diseases 2017, 17(1):300.
24.Titov LP, Zakerbostanabad S, Slizen V, Surkova L, Taghikhani M, Bahrmand A: Molecular characterization of rpoB gene mutations in rifampicine-resistant Mycobacterium tuberculosis isolates from tuberculosis patients in Belarus. Biotechnol J 2006, 1(12):1447–1452.
25.Yu XL, Wen ZL, Chen GZ, Li R, Ding BB, Yao YF, Li Y, Wu H, Guo XK, Wang HH et al: Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolated from south-central in China. The Journal of antibiotics 2014, 67(4):291–297.
26.ElMaraachli W, Slater M, Berrada ZL, Lin SY, Catanzaro A, Desmond E, Rodrigues C, Victor TC, Crudu V, Gler MT et al: Predicting differential rifamycin resistance in clinical Mycobacterium tuberculosis isolates by specific rpoB mutations. Int J Tuberc Lung Dis 2015, 19(10):1222–1226.
27.Pang Y, Lu J, Wang Y, Song Y, Wang S, Zhao Y: Study of the rifampin monoresistance mechanism in Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy 2013, 57(2):893–900.
28.Feuerriegel S, Oberhauser B, George AG, Dafae F, Richter E, Rusch-Gerdes S, Niemann S: Sequence analysis for detection of first-line drug resistance in Mycobacterium tuberculosis strains from a high-incidence setting. BMC microbiology 2012, 12:90.
29.Zaczek A, Brzostek A, Augustynowicz-Kopec E, Zwolska Z, Dziadek J: Genetic evaluation of relationship between mutations in rpoB and resistance of Mycobacterium tuberculosis to rifampin. BMC Microbiol 2009, 9:10.
30.Donnabella V, Martiniuk F, Kinney D, Bacerdo M, Bonk S, Hanna B, Rom WN: Isolation of the gene for the beta subunit of RNA polymerase from rifampicin-resistant Mycobacterium tuberculosis and identification of new mutations. Am J Respir Cell Mol Biol 1994, 11(6):639–643.
31.Moghazeh SL, Pan X, Arain T, Stover CK, Musser JM, Kreiswirth BN: Comparative antimycobacterial activities of rifampin, rifapentine, and KRM–1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Agents Chemother 1996, 40(11):2655–2657.
32.Huang H, Jin Q, Ma Y, Chen X, Zhuang Y: Characterization of rpoB mutations in rifampicin-resistant Mycobacterium tuberculosis isolated in China. Tuberculosis (Edinb) 2002, 82(2–3):79–83.
33.Williams DL, Spring L, Collins L, Miller LP, Heifets LB, Gangadharam PR, Gillis TP: Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998, 42(7):1853–1857.
34.Kapur V, Li LL, Iordanescu S, Hamrick MR, Wanger A, Kreiswirth BN, Musser JM: Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas. J Clin Microbiol 1994, 32(4):1095–1098.
35.Bodmer T, Zurcher G, Imboden P, Telenti A: Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 1995, 35(2):345–348.
36.Herrera L, Jimenez S, Valverde A, Garcia-Aranda MA, Saez-Nieto JA: Molecular analysis of rifampicin-resistant Mycobacterium tuberculosis isolated in Spain (1996–2001). Description of new mutations in the rpoB gene and review of the literature. Int J Antimicrob Agents 2003, 21(5):403–408.
37.Hirano K, Abe C, Takahashi M: Mutations in the rpoB gene of rifampin-resistant Mycobacterium tuberculosis strains isolated mostly in Asian countries and their rapid detection by line probe assay. J Clin Microbiol 1999, 37(8):2663–2666.